GWM
CDTX

Geneos Wealth Management’s Cidara Therapeutics CDTX Stock Holding History

Geneos Wealth Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115
Closed -$5K – 2887
2021
Q1 		$5K Buy
+115
New +$5.68K ﹤0.01% 2634

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geneos Wealth Management's CDTX Position: Q2 2021 in Review

Geneos Wealth Management sold out of Cidara Therapeutics (CDTX) in Q2 2021, closing a stake of 115 shares — an estimated $5K sold.

Geneos Wealth Management first reported a position in CDTX in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 55 funds tracked by Wall St. Rank hold CDTX as of Q2 2021.

  • Geneos Wealth Management reported no remaining Cidara Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 115 Cidara Therapeutics shares in Q2 2021, an estimated $5K.
  • Geneos Wealth Management first reported a position in Cidara Therapeutics in Q1 2021 and held it in 1 quarter.
  • Geneos Wealth Management's Cidara Therapeutics position peaked at $5K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.